Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer

Yu, Ke‐Da; Ye, Fu-Gui; He, Min; Fan, Lei; Ma, Ding; Mo, Miao; Wu, Jiong; Liu, Guang‐Yu; Di, Gen‐Hong; Zeng, Xiaohua; He, Pingqing; Wu, Kejin; Hou, Yifeng; Wang, Jie; Wang, Cheng; Zhuang, Zhigang; Song, Chuangui; Lin, Xiaoyan; Toss, Angela; Ricci, Francesco; Shen, Zhenzhou; Shao, Zhi‐Ming

doi:10.1001/jamaoncol.2020.2965

Public

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer

Published in JAMA Oncology • Aug 14, 2020

Authors:

Ke‐Da Yu

Fu-Gui Ye

Min He

Abstract

Importance: The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective: To compare 6 cycles of paclitaxel plus...

Subject

Medicine

Epirubicin

Carboplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!